|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Aug 11, 2009 |
Title |
Effect of two weeks erythropoietin treatment on monocyte transcriptomes of cardiorenal patients |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Patients with combined heart and renal failure, also termed the cardiorenal syndrome (CRS), have high cardiovascular morbidity and mortality. Several key connectors between heart and kidney have been recognized, such as oxidative stress, inflammation, the renin-angiotensin system and the sympathetic nervous system. Monocytes are key players in the development of atherosclerosis and may act as a biosensor to detect changes in the systemic environment. Anemia, which occurs frequently in CRS, is partly due to an absolute and/or relative erythropoietin (EPO) deficiency. Until now, EPO treatment has largely been used to treat (renal) anemia, but recent research also showed beneficial non-hematopoietic effects such as anti-inflammatory and anti-oxidative capacities. The hypothesis of the present study was that monocyte gene expression profiles of cardiorenal patients compared to healthy controls reflect the systemic nature of CRS and are responsive to short-term treatment with Epo. The first aim was to investigate whether this short term treatment revealed non-hematopoietic EPO effects. The second aim was to address whether EPO dampens expression of genes involved in inflammation and oxidative stress. Given the variable response to EPO, the third aim was to test whether baseline gene expression profiles or the acute gene expression modulation by EPO are associated with EPO resistance.
|
|
|
Overall design |
This study was part of a larger clinical trial in which hematopoietic and non-hematopoietic effects of EPO treatment for short and long term are assessed in CRS patients. Therefore, patients were randomized into 3 groups: (1) EPO, patients are kept on baseline low hemoglobin levels by phlebotomy for 6 months; (2) EPO, patients may rise in hemoglobin levels to defined maximum for 6 months; (3) No EPO. This gene expression analysis is focussed on EPO's short-term (2wk) effects in a subset of included patients. Group (1) and (2) were grouped for analysis, since both groups received EPO and no phlebotomy had been performed in the first 2 weeks. Monocytes were positively isolated from peripheral whole blood with CD14+ immunomagnetic beads. Total RNA was isolated and prepared for genome wide analyses using Illumina HumanRef8 V3.0 Beadchips. In total, 48 arrays were analyzed including 12 healthy controls, 18 CRS patients at baseline and 2 weeks after study enrollment. Twelve out of 18 patients received EPO during the two weeks.
The supplementary file 'GSE17582_non-normalized_data.txt' contains non-normalized data for Samples GSM438053-GSM438100.
|
|
|
Contributor(s) |
Braam B, Gaillard CA, Verhaar MC, Jie KE, Wesseling S, van der Putten K |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
Submission date |
Aug 10, 2009 |
Last update date |
Mar 20, 2017 |
Contact name |
Branko Braam |
E-mail(s) |
bbraam@gmail.com
|
Phone |
780 407 3322
|
Fax |
780 407 7771
|
URL |
http://www.nephrogenomics.net
|
Organization name |
Univ. of Alberta
|
Department |
Medicine / Nephrology
|
Street address |
11-107 CSB
|
City |
Edmonton |
ZIP/Postal code |
T6C 3X6 |
Country |
Canada |
|
|
Platforms (1) |
GPL6883 |
Illumina HumanRef-8 v3.0 expression beadchip |
|
Samples (48)
|
|
Relations |
BioProject |
PRJNA118687 |
Supplementary file |
Size |
Download |
File type/resource |
GSE17582_RAW.tar |
3.9 Mb |
(http)(custom) |
TAR |
GSE17582_non-normalized_data.txt.gz |
5.7 Mb |
(ftp)(http) |
TXT |
Processed data included within Sample table |
|
|
|
|
|